splenic mass workup in Golden
By Ravi Tolwani·April 3, 2026·1 question
🧬Oncology🔪Surgery📷Radiology
🧭 Routing
A splenic mass workup requires oncology for cancer staging and prognosis, surgery for potential biopsy or splenectomy, and radiology for imaging (ultrasound, CT) to characterize the mass and assess for metastasis.
🧬Rachel TorresOncology Specialist
Of course. This is a classic and concerning presentation, especially in a Golden. Let's walk through a systematic approach to give your client clarity and develop a solid plan. My primary concern here is ruling out or confirming hemangiosarcoma (HSA) and ensuring the patient is stable for any intervention.
The "rule of two-thirds" is a helpful, albeit sobering, guide here: roughly two-thirds of splenic masses are malignant, and of those, two-thirds are hemangiosarcoma. Staging before any major procedure is critical to help the owner make an informed decision.
Here is the workup I recommend:
1. Initial Stabilization & Baseline Labs:
* Assess for hemoabdomen: A quick abdominal FAST scan can confirm free fluid. If the patient is unstable (pale, tachycardic, weak), fluid resuscitation is the priority.
* Minimum Database:
* CBC: Look for anemia (regenerative or not), thrombocytopenia, and schistocytes, all of which can suggest microangiopathic processes like HSA.
* Chemistry/UA: General health screen, but also check for any evidence of organ dysfunction that could complicate anesthesia.
* Coagulation Panel (PT/PTT): Disseminated intravascular coagulation (DIC) is a known sequela of HSA. This is a crucial pre-operative check.
2. Staging — The Non-Negotiables:
* Three-View Thoracic Radiographs: This is the most important first step for metastasis check. The right atrium and pulmonary parenchyma are common metastatic sites for HSA. Sarah Lin can provide a formal review, but we're looking for nodules or a globoid cardiac silhouette.
* Full Abdominal Ultrasound: Beyond characterizing the splenic mass itself (complex, cavitated appearance is classic for HSA), we need to meticulously evaluate the liver, mesentery, and regional lymph nodes for metastatic disease. The "double-pop" sign of an actively bleeding splenic mass is often seen.
* Echocardiogram: I strongly recommend this pre-operatively. A right atrial mass is present in up to 25% of dogs with splenic HSA. Finding one significantly changes the prognosis and the conversation about proceeding with a splenectomy.
3. The Next Step: Surgery vs. Euthanasia
If staging is clear of gross metastasis, splenectomy is both diagnostic and therapeutic. James Okafor can advise on the surgical plan. The key is to counsel the owner that the goal of surgery is to obtain a definitive diagnosis via histopathology and resolve the immediate risk of hemorrhage.
The prognosis is entirely dependent on the histopath result.
* Benign (hematoma, nodular hyperplasia): Surgery is curative.
* Hemangiosarcoma: With splenectomy alone, the median survival time (MST) is unfortunately only 1-3 months. With adjuvant doxorubicin-based chemotherapy, we can extend that to approximately 6 months.
My role is to help you frame this for the client: the workup gives us the information to decide if surgery is a reasonable option. If we find widespread disease, we can pivot to a palliative care plan. If not, we proceed to surgery knowing we have a plan for what comes next.
The "rule of two-thirds" is a helpful, albeit sobering, guide here: roughly two-thirds of splenic masses are malignant, and of those, two-thirds are hemangiosarcoma. Staging before any major procedure is critical to help the owner make an informed decision.
Here is the workup I recommend:
1. Initial Stabilization & Baseline Labs:
* Assess for hemoabdomen: A quick abdominal FAST scan can confirm free fluid. If the patient is unstable (pale, tachycardic, weak), fluid resuscitation is the priority.
* Minimum Database:
* CBC: Look for anemia (regenerative or not), thrombocytopenia, and schistocytes, all of which can suggest microangiopathic processes like HSA.
* Chemistry/UA: General health screen, but also check for any evidence of organ dysfunction that could complicate anesthesia.
* Coagulation Panel (PT/PTT): Disseminated intravascular coagulation (DIC) is a known sequela of HSA. This is a crucial pre-operative check.
2. Staging — The Non-Negotiables:
* Three-View Thoracic Radiographs: This is the most important first step for metastasis check. The right atrium and pulmonary parenchyma are common metastatic sites for HSA. Sarah Lin can provide a formal review, but we're looking for nodules or a globoid cardiac silhouette.
* Full Abdominal Ultrasound: Beyond characterizing the splenic mass itself (complex, cavitated appearance is classic for HSA), we need to meticulously evaluate the liver, mesentery, and regional lymph nodes for metastatic disease. The "double-pop" sign of an actively bleeding splenic mass is often seen.
* Echocardiogram: I strongly recommend this pre-operatively. A right atrial mass is present in up to 25% of dogs with splenic HSA. Finding one significantly changes the prognosis and the conversation about proceeding with a splenectomy.
3. The Next Step: Surgery vs. Euthanasia
If staging is clear of gross metastasis, splenectomy is both diagnostic and therapeutic. James Okafor can advise on the surgical plan. The key is to counsel the owner that the goal of surgery is to obtain a definitive diagnosis via histopathology and resolve the immediate risk of hemorrhage.
The prognosis is entirely dependent on the histopath result.
* Benign (hematoma, nodular hyperplasia): Surgery is curative.
* Hemangiosarcoma: With splenectomy alone, the median survival time (MST) is unfortunately only 1-3 months. With adjuvant doxorubicin-based chemotherapy, we can extend that to approximately 6 months.
My role is to help you frame this for the client: the workup gives us the information to decide if surgery is a reasonable option. If we find widespread disease, we can pivot to a palliative care plan. If not, we proceed to surgery knowing we have a plan for what comes next.
🔪James OkaforSurgery Specialist
From a surgical standpoint, a splenic mass in a Golden Retriever is treated as a high-risk finding until proven otherwise. My primary concerns are hemangiosarcoma (HSA) and the potential for imminent, life-threatening hemoabdomen. My workup is focused on staging the patient and assessing their fitness for surgery.
1. Stability & Staging:
First, is the patient stable? If there's evidence of active bleeding (pale gums, tachycardia, fluid wave), this becomes an emergency stabilization and surgical case. Assuming they are stable, staging is non-negotiable before a planned procedure.
* Imaging: I rely on Dr. Lin for a thorough abdominal ultrasound, but I also need three-view thoracic radiographs or, ideally, a chest CT to screen for pulmonary metastasis. Evidence of metastasis fundamentally changes the goals of surgery and the owner's decision-making.
* Cardiac Screen: A baseline ECG is essential to check for ventricular arrhythmias, which are common with splenic disease and anesthesia. Given the high incidence of concurrent right atrial HSA, I strongly recommend a screening cardiac ultrasound. Finding a cardiac mass makes the prognosis grave.
* Hematology: A CBC to assess for anemia and thrombocytopenia is critical, as is a coagulation panel (PT/PTT). Disseminated intravascular coagulation (DIC) is a significant perioperative risk.
2. Surgical Plan & Owner Communication:
The procedure is a total splenectomy. The conversation with the owner is direct: even with a negative metastatic check, there's a high probability of malignancy. The surgery is both therapeutic (removes the ticking time bomb in the abdomen) and diagnostic (histopathology is the only way to get a definitive answer).
If staging is clean and the owner consents, we proceed. If the mass has already ruptured, the priority shifts to hemorrhage control, and the staging workup may have to happen concurrently or be abbreviated.
Post-operatively, the entire spleen is submitted for histopathology. The results will determine the next steps, which is where Dr. Torres's expertise in oncology becomes essential for discussing adjuvant chemotherapy.
1. Stability & Staging:
First, is the patient stable? If there's evidence of active bleeding (pale gums, tachycardia, fluid wave), this becomes an emergency stabilization and surgical case. Assuming they are stable, staging is non-negotiable before a planned procedure.
* Imaging: I rely on Dr. Lin for a thorough abdominal ultrasound, but I also need three-view thoracic radiographs or, ideally, a chest CT to screen for pulmonary metastasis. Evidence of metastasis fundamentally changes the goals of surgery and the owner's decision-making.
* Cardiac Screen: A baseline ECG is essential to check for ventricular arrhythmias, which are common with splenic disease and anesthesia. Given the high incidence of concurrent right atrial HSA, I strongly recommend a screening cardiac ultrasound. Finding a cardiac mass makes the prognosis grave.
* Hematology: A CBC to assess for anemia and thrombocytopenia is critical, as is a coagulation panel (PT/PTT). Disseminated intravascular coagulation (DIC) is a significant perioperative risk.
2. Surgical Plan & Owner Communication:
The procedure is a total splenectomy. The conversation with the owner is direct: even with a negative metastatic check, there's a high probability of malignancy. The surgery is both therapeutic (removes the ticking time bomb in the abdomen) and diagnostic (histopathology is the only way to get a definitive answer).
If staging is clean and the owner consents, we proceed. If the mass has already ruptured, the priority shifts to hemorrhage control, and the staging workup may have to happen concurrently or be abbreviated.
Post-operatively, the entire spleen is submitted for histopathology. The results will determine the next steps, which is where Dr. Torres's expertise in oncology becomes essential for discussing adjuvant chemotherapy.
📷Sarah LinRadiology Specialist
Colleague,
The workup for a splenic mass in a Golden Retriever requires a systematic and thorough approach, as this signalment carries a high index of suspicion for hemangiosarcoma. Our primary goals with imaging are to stage the patient, identify acute complications like hemoabdomen, and guide the subsequent clinical and surgical plan.
My team has provided their detailed assessments. Here is my synthesis.
1. Staging: Thoracic Radiography
As my Thoracic Reader detailed, a three-view thoracic series (right lateral, left lateral, VD) is the non-negotiable first step for staging. We are looking for two primary signs of metastasis:
* Pulmonary Nodules: A nodular interstitial pattern is the classic finding. Be aware that radiographs are insensitive to nodules smaller than 7-10mm; chest CT is the gold standard for a definitive metastasis check if the client is pursuing aggressive therapy.
* Pericardial Effusion: Look for a globoid cardiac silhouette. Right atrial hemangiosarcoma is a common site of metastasis and can lead to hemopericardium.
2. Abdominal Assessment: Radiographs & Ultrasound
My Abdominal Reader correctly positioned survey radiographs as the tool to confirm a mass, assess its gross displacement of adjacent organs (mass effect), and, critically, evaluate for hemoabdomen via loss of serosal detail.
However, abdominal ultrasound is essential for characterization. My Ultrasound Interpreter outlined the comprehensive protocol:
* Mass Evaluation: Assess the splenic mass architecture (complex, cavitated, solid) and capsular integrity.
* Metastasis Hunt: Systematically evaluate the liver parenchyma for nodules, and assess the mesenteric and sublumbar lymph nodes for changes.
* Fluid Assessment: An AFAST scan should be performed to identify and characterize any free fluid. Echogenic, swirling fluid is highly suggestive of active hemorrhage.
3. Critical Point of Interpretation
This is the single most important takeaway: ultrasound cannot reliably differentiate a benign hematoma from a malignant neoplasm like hemangiosarcoma. Both can appear as large, cavitated, bleeding masses. Do not over-interpret the ultrasound findings to the client. The definitive diagnosis is always histopathology.
Summary & Recommendation
The combination of three-view thoracic radiographs and a complete abdominal ultrasound provides the necessary information for initial staging and surgical planning. If no gross metastatic disease is identified, the standard of care is splenectomy with histopathology. If metastatic disease is found, the imaging findings will be critical for your discussion with the owner regarding prognosis and palliative care options.
The workup for a splenic mass in a Golden Retriever requires a systematic and thorough approach, as this signalment carries a high index of suspicion for hemangiosarcoma. Our primary goals with imaging are to stage the patient, identify acute complications like hemoabdomen, and guide the subsequent clinical and surgical plan.
My team has provided their detailed assessments. Here is my synthesis.
1. Staging: Thoracic Radiography
As my Thoracic Reader detailed, a three-view thoracic series (right lateral, left lateral, VD) is the non-negotiable first step for staging. We are looking for two primary signs of metastasis:
* Pulmonary Nodules: A nodular interstitial pattern is the classic finding. Be aware that radiographs are insensitive to nodules smaller than 7-10mm; chest CT is the gold standard for a definitive metastasis check if the client is pursuing aggressive therapy.
* Pericardial Effusion: Look for a globoid cardiac silhouette. Right atrial hemangiosarcoma is a common site of metastasis and can lead to hemopericardium.
2. Abdominal Assessment: Radiographs & Ultrasound
My Abdominal Reader correctly positioned survey radiographs as the tool to confirm a mass, assess its gross displacement of adjacent organs (mass effect), and, critically, evaluate for hemoabdomen via loss of serosal detail.
However, abdominal ultrasound is essential for characterization. My Ultrasound Interpreter outlined the comprehensive protocol:
* Mass Evaluation: Assess the splenic mass architecture (complex, cavitated, solid) and capsular integrity.
* Metastasis Hunt: Systematically evaluate the liver parenchyma for nodules, and assess the mesenteric and sublumbar lymph nodes for changes.
* Fluid Assessment: An AFAST scan should be performed to identify and characterize any free fluid. Echogenic, swirling fluid is highly suggestive of active hemorrhage.
3. Critical Point of Interpretation
This is the single most important takeaway: ultrasound cannot reliably differentiate a benign hematoma from a malignant neoplasm like hemangiosarcoma. Both can appear as large, cavitated, bleeding masses. Do not over-interpret the ultrasound findings to the client. The definitive diagnosis is always histopathology.
Summary & Recommendation
The combination of three-view thoracic radiographs and a complete abdominal ultrasound provides the necessary information for initial staging and surgical planning. If no gross metastatic disease is identified, the standard of care is splenectomy with histopathology. If metastatic disease is found, the imaging findings will be critical for your discussion with the owner regarding prognosis and palliative care options.
Thoracic Reader
A three-view thoracic radiographic series is a critical component of the metastatic workup for a Golden Retriever with a suspected splenic mass, given the high metastatic potential of many splenic neoplasms, particularly hemangiosarcoma (HSA), which is prevalent in this breed.
---
I. Protocol for Three-View Thoracic Radiography
A. Patient Preparation:
Identification: Confirm patient identity via microchip and signalment.
Clinical Assessment: Briefly assess respiratory rate, effort, and overall demeanor.
Sedation: Sedation is often beneficial for optimal patient positioning, comfort, and to minimize motion artifact, especially in painful or anxious patients. Specific drug doses are not provided here as no formulary data was supplied.
Artifact Removal: Remove collar, harness, or any other external objects that could obscure anatomy or create artifacts.
B. Radiographic Views:
All images should be acquired at peak inspiration to maximize lung inflation and minimize superimposition of structures.
Right Lateral (R-Lat):
* Positioning: Patient in right lateral recumbency. Forelimbs extended cranially, hindlimbs extended caudally. Sternum and vertebral column should be superimposed.
* Purpose: Best for evaluating the left lung lobes, caudal vena cava, and often provides better visualization of the cardiac silhouette for VHS measurement due to less superimposition of the right cranial lung lobe.
Left Lateral (L-Lat):
* Positioning: Patient in left lateral recumbency. Forelimbs extended cranially, hindlimbs extended caudally. Sternum and vertebral column should be superimposed.
* Purpose: Best for evaluating the right lung lobes and assessing the pulmonary vessels.
Ventrodorsal (VD):
* Positioning: Patient in dorsal recumbency. Forelimbs extended cranially and symmetrically, hindlimbs extended caudally. Sternum and vertebral column should be superimposed and centered in the image.
* Purpose: Provides a different projection to minimize superimposition of lung parenchyma, crucial for detecting small nodules. Offers excellent visualization of the caudal lung fields and diaphragm.
C. Exposure Settings & Image Quality:
* Settings: Use appropriate kVp and mAs for a large breed dog to ensure adequate penetration of the mediastinum and cardiac silhouette while maintaining good contrast within the lung parenchyma.
* Quality: Images should be well-penetrated, well-centered, free of motion artifact, and acquired at peak inspiration. All lung fields, from the thoracic inlet to the diaphragmatic crura, must be included.
---
II. Key Findings: Metastasis Check and Systematic Review
A systematic approach is crucial for thorough evaluation.
A. Cardiac Silhouette:
* Size & Shape: Evaluate the overall size and shape of the heart. Measure the Vertebral Heart Score (VHS) for an objective assessment (normal range for Golden Retrievers can be slightly higher than other breeds, often 10.5-11.5v, but interpret in context).
* Pericardial Effusion: Look for a globally enlarged, rounded, or "globoid" cardiac silhouette. This is a critical finding in Golden Retrievers with splenic masses, as hemangiosarcoma commonly metastasizes to the right atrium/auricle, leading to hemopericardium. Other signs include widening of the caudal vena cava and potential pleural effusion.
B. Lung Patterns (Primary Focus for Metastasis):
* Nodular Interstitial Pattern: This is the hallmark of pulmonary metastasis.
* Characteristics: Look for discrete, soft tissue opaque nodules within the lung parenchyma.
* Number & Size: They can be solitary or multiple, ranging from very small (<5mm) to large ("cannonball" metastases). Radiography has limitations in detecting very small nodules (<5-7mm).
* Distribution: Often randomly distributed throughout the lung fields.
* Margins: Usually well-defined, but can be ill-defined or cavitated (especially with HSA).
* Unstructured Interstitial Pattern: A diffuse, hazy increase in lung opacity without distinct nodules or bronchial thickening. Can represent early or diffuse infiltrative metastatic disease (e.g., carcinomatosis), edema, or fibrosis.
* Alveolar Pattern: While less common for direct metastasis, severe hemorrhage from a cavitated metastatic lesion or a primary lung tumor could cause an alveolar pattern.
* Vascularity: Assess the size and tortuosity of pulmonary arteries and veins.
**C. Medi
---
I. Protocol for Three-View Thoracic Radiography
A. Patient Preparation:
B. Radiographic Views:
All images should be acquired at peak inspiration to maximize lung inflation and minimize superimposition of structures.
* Positioning: Patient in right lateral recumbency. Forelimbs extended cranially, hindlimbs extended caudally. Sternum and vertebral column should be superimposed.
* Purpose: Best for evaluating the left lung lobes, caudal vena cava, and often provides better visualization of the cardiac silhouette for VHS measurement due to less superimposition of the right cranial lung lobe.
* Positioning: Patient in left lateral recumbency. Forelimbs extended cranially, hindlimbs extended caudally. Sternum and vertebral column should be superimposed.
* Purpose: Best for evaluating the right lung lobes and assessing the pulmonary vessels.
* Positioning: Patient in dorsal recumbency. Forelimbs extended cranially and symmetrically, hindlimbs extended caudally. Sternum and vertebral column should be superimposed and centered in the image.
* Purpose: Provides a different projection to minimize superimposition of lung parenchyma, crucial for detecting small nodules. Offers excellent visualization of the caudal lung fields and diaphragm.
C. Exposure Settings & Image Quality:
* Settings: Use appropriate kVp and mAs for a large breed dog to ensure adequate penetration of the mediastinum and cardiac silhouette while maintaining good contrast within the lung parenchyma.
* Quality: Images should be well-penetrated, well-centered, free of motion artifact, and acquired at peak inspiration. All lung fields, from the thoracic inlet to the diaphragmatic crura, must be included.
---
II. Key Findings: Metastasis Check and Systematic Review
A systematic approach is crucial for thorough evaluation.
A. Cardiac Silhouette:
* Size & Shape: Evaluate the overall size and shape of the heart. Measure the Vertebral Heart Score (VHS) for an objective assessment (normal range for Golden Retrievers can be slightly higher than other breeds, often 10.5-11.5v, but interpret in context).
* Pericardial Effusion: Look for a globally enlarged, rounded, or "globoid" cardiac silhouette. This is a critical finding in Golden Retrievers with splenic masses, as hemangiosarcoma commonly metastasizes to the right atrium/auricle, leading to hemopericardium. Other signs include widening of the caudal vena cava and potential pleural effusion.
B. Lung Patterns (Primary Focus for Metastasis):
* Nodular Interstitial Pattern: This is the hallmark of pulmonary metastasis.
* Characteristics: Look for discrete, soft tissue opaque nodules within the lung parenchyma.
* Number & Size: They can be solitary or multiple, ranging from very small (<5mm) to large ("cannonball" metastases). Radiography has limitations in detecting very small nodules (<5-7mm).
* Distribution: Often randomly distributed throughout the lung fields.
* Margins: Usually well-defined, but can be ill-defined or cavitated (especially with HSA).
* Unstructured Interstitial Pattern: A diffuse, hazy increase in lung opacity without distinct nodules or bronchial thickening. Can represent early or diffuse infiltrative metastatic disease (e.g., carcinomatosis), edema, or fibrosis.
* Alveolar Pattern: While less common for direct metastasis, severe hemorrhage from a cavitated metastatic lesion or a primary lung tumor could cause an alveolar pattern.
* Vascularity: Assess the size and tortuosity of pulmonary arteries and veins.
**C. Medi
Abdominal Reader
Survey abdominal radiographs are a critical initial diagnostic tool in a Golden Retriever with a suspected splenic mass, providing valuable information regarding the presence of a mass, its effects on surrounding structures, and evidence of complications like hemoabdomen.
Utility of Survey Abdominal Radiographs:
Initial Assessment: Provides a rapid, non-invasive overview of the abdominal cavity.
Confirmation of Mass Presence: Can confirm the presence of an abdominal mass, localize it to the cranial/mid-abdomen, and suggest a splenic origin.
Assessment for Mass Effect: Evaluates displacement of adjacent organs, which helps characterize the mass's size and location.
Detection of Hemoperitoneum (Hemoabdomen): Identifies signs consistent with free abdominal fluid, a common and life-threatening complication of splenic masses (especially hemangiosarcoma).
Exclusion of Other Pathologies: Helps rule out other causes of acute abdominal signs (e.g., GI foreign body, GDV, severe enteritis).
Pre-surgical Planning: Can guide further diagnostics (e.g., ultrasound) and inform surgical approach.
Expected Radiographic Findings:
1. Splenic Mass:
* Location: Typically appears as a soft tissue opacity in the cranial or mid-abdomen, often extending from the left cranial quadrant across the midline.
* Size and Shape: Can be focal (discrete, rounded, or lobulated mass) or diffuse (generalized splenomegaly). Large masses may obscure normal organ margins.
* Opacity: Homogeneous soft tissue opacity. Mineralization is rare but can occur.
* Margination: Margins may be well-defined or poorly defined, especially if very large or if significant free fluid is present.
2. Mass Effect:
* Gastric Displacement: The stomach (fundus and body) is commonly displaced caudally and/or medially by a cranial splenic mass.
* Small Intestine Displacement: Small intestinal loops are typically displaced ventrally and/or caudally, or compressed against the right abdominal wall.
* Left Kidney Displacement: The left kidney may be displaced caudally or medially.
* Diaphragmatic Displacement: Very large cranial masses can cause mild cranial displacement of the diaphragm.
3. Hemoabdomen (Peritoneal Effusion):
* Loss of Serosal Detail: The most prominent sign. The normally sharp outlines of abdominal organs (liver, spleen, kidneys, intestines) become indistinct or completely effaced, resulting in a "ground glass" or "muddy" appearance. This occurs as fluid fills the spaces between organs.
* Abdominal Distension: The abdomen may appear distended, with the abdominal wall bulging.
* Centralization/Floating of Bowel Loops: Gas-filled small intestinal loops may appear to float centrally within the fluid-filled abdomen, often displaced from the abdominal wall.
* Generalized Soft Tissue Opacity: The entire abdomen may appear diffusely more opaque due to the presence of fluid.
Limitations:
While informative, survey radiographs cannot definitively differentiate between benign (e.g., hematoma, benign hyperplasia) and malignant (e.g., hemangiosarcoma) splenic masses. They are also insensitive for small splenic lesions or early metastatic disease. Further diagnostics, particularly abdominal ultrasound, are essential for detailed characterization of the mass, assessment of other abdominal organs, and guided aspirates/biopsies. Thoracic radiographs are also crucial to screen for pulmonary metastasis, especially in breeds predisposed to hemangiosarcoma like Golden Retrievers.
Utility of Survey Abdominal Radiographs:
Expected Radiographic Findings:
1. Splenic Mass:
* Location: Typically appears as a soft tissue opacity in the cranial or mid-abdomen, often extending from the left cranial quadrant across the midline.
* Size and Shape: Can be focal (discrete, rounded, or lobulated mass) or diffuse (generalized splenomegaly). Large masses may obscure normal organ margins.
* Opacity: Homogeneous soft tissue opacity. Mineralization is rare but can occur.
* Margination: Margins may be well-defined or poorly defined, especially if very large or if significant free fluid is present.
2. Mass Effect:
* Gastric Displacement: The stomach (fundus and body) is commonly displaced caudally and/or medially by a cranial splenic mass.
* Small Intestine Displacement: Small intestinal loops are typically displaced ventrally and/or caudally, or compressed against the right abdominal wall.
* Left Kidney Displacement: The left kidney may be displaced caudally or medially.
* Diaphragmatic Displacement: Very large cranial masses can cause mild cranial displacement of the diaphragm.
3. Hemoabdomen (Peritoneal Effusion):
* Loss of Serosal Detail: The most prominent sign. The normally sharp outlines of abdominal organs (liver, spleen, kidneys, intestines) become indistinct or completely effaced, resulting in a "ground glass" or "muddy" appearance. This occurs as fluid fills the spaces between organs.
* Abdominal Distension: The abdomen may appear distended, with the abdominal wall bulging.
* Centralization/Floating of Bowel Loops: Gas-filled small intestinal loops may appear to float centrally within the fluid-filled abdomen, often displaced from the abdominal wall.
* Generalized Soft Tissue Opacity: The entire abdomen may appear diffusely more opaque due to the presence of fluid.
Limitations:
While informative, survey radiographs cannot definitively differentiate between benign (e.g., hematoma, benign hyperplasia) and malignant (e.g., hemangiosarcoma) splenic masses. They are also insensitive for small splenic lesions or early metastatic disease. Further diagnostics, particularly abdominal ultrasound, are essential for detailed characterization of the mass, assessment of other abdominal organs, and guided aspirates/biopsies. Thoracic radiographs are also crucial to screen for pulmonary metastasis, especially in breeds predisposed to hemangiosarcoma like Golden Retrievers.
Ultrasound Interpreter
A systematic abdominal ultrasound examination for a splenic mass workup in a Golden Retriever requires a thorough assessment of the spleen itself, the entire abdominal cavity for evidence of metastasis or concurrent disease, and the presence and character of free fluid.
Begin with a systematic approach, typically scanning the abdomen in quadrants or using an organ-by-organ method to ensure no area is missed. A common approach involves:
Spleen: Full assessment, including the mass.
Liver & Gallbladder: Full assessment.
Kidneys: Both left and right.
Adrenal Glands: Both left and right.
Gastrointestinal Tract: Stomach, small intestine, colon.
Pancreas: Body and limbs.
Urinary Bladder & Urethra (proximal).
Lymph Nodes: Mesenteric, sublumbar.
Vascular Structures: Aorta, caudal vena cava, portal vein.
Free Fluid: AFAST scan (Diaphragmaticohepatic, Splenorenal, Cystocolic, Hepatorenal views).
* Overall Size and Shape: Note any generalized splenomegaly or architectural distortion.
* Splenic Mass(es):
* Location: Identify the specific lobe or region (head, body, tail).
* Size: Three orthogonal dimensions.
* Echogenicity: Describe the internal architecture (e.g., anechoic, hypoechoic, hyperechoic, mixed, cavitated, solid). Note any areas of mineralization, hemorrhage, or necrosis.
* Margination: Well-defined, irregular, infiltrative.
* Capsular Integrity: Assess for evidence of rupture or focal capsular disruption, which may indicate active hemorrhage.
* Vascularity (Doppler): Assess blood flow within and around the mass using Color and Power Doppler. Note presence, pattern (e.g., peripheral, central, chaotic), and resistance indices (RI) if measurable, though RI alone is not diagnostic.
* Remaining Splenic Parenchyma: Scan the entire spleen for additional nodules, diffuse changes (e.g., hyperechoic myelolipomas, diffuse infiltration), or evidence of other disease.
* Liver:
* Size, Shape, Margins: Evaluate overall liver size and contour.
* Parenchymal Echogenicity: Assess for diffuse changes (e.g., hyperechoic fatty infiltration, hypoechoic congestion).
* Focal Lesions: Carefully scan for hepatic masses or nodules suggestive of metastasis. Describe size, echogenicity, and vascularity.
* Gallbladder: Evaluate for distension, wall thickening, sludge, or choleliths.
* Kidneys:
* Size, Shape, Corticomedullary Distinction: Assess for hydronephrosis, pyelonephritis, or diffuse parenchymal disease.
* Focal Lesions: Look for renal masses or nodules.
* Adrenal Glands:
* Size and Shape: Measure thickness in transverse view. Evaluate for asymmetry or focal enlargement, which could indicate metastatic disease or a primary adrenal tumor.
* Gastrointestinal Tract:
* Stomach, Small Intestine, Colon: Assess wall thickness, layering, and peristalsis. Look for intraluminal masses, foreign bodies, or mural lesions.
* Mesenteric Lymph Nodes:
* Size, Shape, Echogenicity: Evaluate for enlargement (>5-7mm in short axis), loss of normal reniform shape, or altered echotexture (e.g., hypoechoic cortex, mottled appearance), suggestive of reactive lymphadenopathy, inflammation, or metastasis.
* Sublumbar Lymph Nodes: (Medial iliac, sacral)
* Size, Shape, Echogenicity: Assess for similar changes as mesenteric lymph nodes.
* Pancreas:
* Echogenicity and Margins: Evaluate for evidence of pancreatitis (hypoechoic, irregular margins, peripancreatic fluid) or pancreatic masses.
* Urinary Bladder:
* Wall Thickness, Lumen: Assess for masses, calculi, or wall abnormalities.
* Presence: Perform an AFAST (Abdominal Focused Assessment with Sonography for Trauma/Triage) scan to systematically identify free fluid in the abdomen.
* Location and Volume: Note the specific locations where fluid is present (e.g., perihepatic, perisplenic, paracolic, vesicourachal space). Quantify the volume using the AFAST scoring system if applicable.
* Character:
* Anechoic: Suggests transudate, urine, or fresh hemorrhage.
* Echogenic/Swirling: Highly suggestive of hemorrhage, especially if swirling is observed. May also indicate exudate.
* Fibrin Strands/Clots: Further supports hemorrhage or significant inflammatory exudate.
* Aspiration: If free fluid is present, ultrasound-guided abdominocentesis is often indicated for cytologic evaluation (e.g., PCV of fluid vs. peripheral blood to confirm hemorrhage, presence of neoplastic cells).
It is critically important to understand that ultrasound alone cannot definitively differentiate between benign and malignant splenic masses. While certain features may increase suspicion for malignancy (e.g., highly heterogeneous appearance, cavitations, irregular margins, rapid growth, presence of other abdominal masses/metastasis), these are not pathognomonic.
* Benign Lesions: Splenic hematomas, hemangiomas, myelolipomas, and extramedullary hematopoiesis can appear highly variable and often mimic malignant tumors on ultrasound, including having cavitations and heterogeneous echotexture. A ruptured hematoma can cause significant hemoperitoneum.
* Malignant Lesions: Hemangiosarcoma (HSA) is a common and aggressive splenic malignancy in Golden Retrievers. Other possibilities include histiocytic sarcoma, lymphoma, and other sarcomas. These can also present with a wide range of sonographic appearances.
Therefore, any splenic mass, especially in a high-risk breed like a Golden Retriever, should be approached with a high index of suspicion. Definitive diagnosis requires histopathologic examination of the mass following splenectomy or biopsy. Ultrasound's role is to characterize the mass, identify concurrent disease or metastasis, assess for hemorrhage, and guide treatment planning (e.g., surgical vs. palliative).
(Note: No drug doses were provided in the prompt, so none are included in this response.)
I. Systematic Abdominal Ultrasound Examination
Begin with a systematic approach, typically scanning the abdomen in quadrants or using an organ-by-organ method to ensure no area is missed. A common approach involves:
II. Spleen Assessment
* Overall Size and Shape: Note any generalized splenomegaly or architectural distortion.
* Splenic Mass(es):
* Location: Identify the specific lobe or region (head, body, tail).
* Size: Three orthogonal dimensions.
* Echogenicity: Describe the internal architecture (e.g., anechoic, hypoechoic, hyperechoic, mixed, cavitated, solid). Note any areas of mineralization, hemorrhage, or necrosis.
* Margination: Well-defined, irregular, infiltrative.
* Capsular Integrity: Assess for evidence of rupture or focal capsular disruption, which may indicate active hemorrhage.
* Vascularity (Doppler): Assess blood flow within and around the mass using Color and Power Doppler. Note presence, pattern (e.g., peripheral, central, chaotic), and resistance indices (RI) if measurable, though RI alone is not diagnostic.
* Remaining Splenic Parenchyma: Scan the entire spleen for additional nodules, diffuse changes (e.g., hyperechoic myelolipomas, diffuse infiltration), or evidence of other disease.
III. Other Organ Assessment
* Liver:
* Size, Shape, Margins: Evaluate overall liver size and contour.
* Parenchymal Echogenicity: Assess for diffuse changes (e.g., hyperechoic fatty infiltration, hypoechoic congestion).
* Focal Lesions: Carefully scan for hepatic masses or nodules suggestive of metastasis. Describe size, echogenicity, and vascularity.
* Gallbladder: Evaluate for distension, wall thickening, sludge, or choleliths.
* Kidneys:
* Size, Shape, Corticomedullary Distinction: Assess for hydronephrosis, pyelonephritis, or diffuse parenchymal disease.
* Focal Lesions: Look for renal masses or nodules.
* Adrenal Glands:
* Size and Shape: Measure thickness in transverse view. Evaluate for asymmetry or focal enlargement, which could indicate metastatic disease or a primary adrenal tumor.
* Gastrointestinal Tract:
* Stomach, Small Intestine, Colon: Assess wall thickness, layering, and peristalsis. Look for intraluminal masses, foreign bodies, or mural lesions.
* Mesenteric Lymph Nodes:
* Size, Shape, Echogenicity: Evaluate for enlargement (>5-7mm in short axis), loss of normal reniform shape, or altered echotexture (e.g., hypoechoic cortex, mottled appearance), suggestive of reactive lymphadenopathy, inflammation, or metastasis.
* Sublumbar Lymph Nodes: (Medial iliac, sacral)
* Size, Shape, Echogenicity: Assess for similar changes as mesenteric lymph nodes.
* Pancreas:
* Echogenicity and Margins: Evaluate for evidence of pancreatitis (hypoechoic, irregular margins, peripancreatic fluid) or pancreatic masses.
* Urinary Bladder:
* Wall Thickness, Lumen: Assess for masses, calculi, or wall abnormalities.
IV. Free Fluid Assessment
* Presence: Perform an AFAST (Abdominal Focused Assessment with Sonography for Trauma/Triage) scan to systematically identify free fluid in the abdomen.
* Location and Volume: Note the specific locations where fluid is present (e.g., perihepatic, perisplenic, paracolic, vesicourachal space). Quantify the volume using the AFAST scoring system if applicable.
* Character:
* Anechoic: Suggests transudate, urine, or fresh hemorrhage.
* Echogenic/Swirling: Highly suggestive of hemorrhage, especially if swirling is observed. May also indicate exudate.
* Fibrin Strands/Clots: Further supports hemorrhage or significant inflammatory exudate.
* Aspiration: If free fluid is present, ultrasound-guided abdominocentesis is often indicated for cytologic evaluation (e.g., PCV of fluid vs. peripheral blood to confirm hemorrhage, presence of neoplastic cells).
V. Limitations in Differentiating Benign from Malignant Etiologies
It is critically important to understand that ultrasound alone cannot definitively differentiate between benign and malignant splenic masses. While certain features may increase suspicion for malignancy (e.g., highly heterogeneous appearance, cavitations, irregular margins, rapid growth, presence of other abdominal masses/metastasis), these are not pathognomonic.
* Benign Lesions: Splenic hematomas, hemangiomas, myelolipomas, and extramedullary hematopoiesis can appear highly variable and often mimic malignant tumors on ultrasound, including having cavitations and heterogeneous echotexture. A ruptured hematoma can cause significant hemoperitoneum.
* Malignant Lesions: Hemangiosarcoma (HSA) is a common and aggressive splenic malignancy in Golden Retrievers. Other possibilities include histiocytic sarcoma, lymphoma, and other sarcomas. These can also present with a wide range of sonographic appearances.
Therefore, any splenic mass, especially in a high-risk breed like a Golden Retriever, should be approached with a high index of suspicion. Definitive diagnosis requires histopathologic examination of the mass following splenectomy or biopsy. Ultrasound's role is to characterize the mass, identify concurrent disease or metastasis, assess for hemorrhage, and guide treatment planning (e.g., surgical vs. palliative).
(Note: No drug doses were provided in the prompt, so none are included in this response.)
Related Cases
Canine Melanoma Oral Treatment Vaccine
🧬 Oncology🔪 Surgery📷 Radiology
1 question
Dog Lipoma vs Liposarcoma Difference
🧬 Oncology🔪 Surgery📷 Radiology
1 question
Canine Transitional Cell Carcinoma Bladder
🧬 Oncology🔪 Surgery📷 Radiology
1 question
Feline Injection Site Sarcoma Treatment
🧬 Oncology🔪 Surgery📷 Radiology
1 question
Feline Injection Site Sarcoma Treatment
🧬 Oncology🔪 Surgery📷 Radiology
1 question
7yo golden retriever with a splenic mass on ultrasound
🧬 Oncology🔪 Surgery📷 Radiology
1 question
Get Instant Specialist Consults
DVM Rounds connects you with 13 AI veterinary specialists and 45+ sub-agents. Ask any clinical question and get comprehensive, multi-specialist answers in seconds.
Start Free — No Credit Card